Targeting the fatty acid oxidation in combination with chemotherapy induces complete pancreatic cancer regression in vivo

Targeting the fatty acid oxidation in combination with chemotherapy induces complete pancreatic cancer regression in vivo

Targeting the fatty acid oxidation in combination with chemotherapy induces complete pancreatic cancer regression in vivo 1125 1625 Metabolism & Cancer
3 Comments
  • Serena Castelli
    Serena C 27 May 2021 at 11 h 48 min

    Hi Gabriela, thanks for your poster. I’d like to know if you have evaluated ROS levels in your system. Another question regards the experiment in Fig. 1, did you count live cells after treatment with inhibitors? Thank you

  • Gabriela Reyes Castellanos
    Gabriela R 27 May 2021 at 13 h 40 min

    Thank you Serena for your interesting questions. For the first one, we are currently evaluating ROS levels. In fact, high responder cells to FAO targeting, seem to have higher basal ROS levels. Moreover, Perhexiline treatment is a ROS inductor (dose-dependent), and could increase ROS levels combined with Gemcitabine. For the second question, the assay was done injecting low concentrations of the inhibitors directly during OCR measurements, We didn’t evaluate cell viability after the assay, but in cell viability assays we demonstrate that Etomoxir at the used dose (4 microM) has no impact on cell viability in any of the cells. Good day.

  • Serena Castelli
    Serena C 27 May 2021 at 14 h 08 min

    OK, thank you.
    Good day to you too

Comments are closed.

C2M2NF, A core model of central metabolism with Carbon, Nitrogen and Folate pathways: application to One-carbon metabolism in cancer cells
Targeting the metabolic vulnerabilities of metastatic colorectal cancer
The role of adipocyte G0/G1 Switch Gene 2 (G0S2) in the crosstalk between cancer cells and adipocytes
Mitochondrial complex I null cancer models reveal unspecific antiproliferative effects of complex I inhibitors – Copie
Enter your
text here